CBT124 (bevacizumab biosimilar) / Cipla, Bio Mabs - LARVOL DELTA

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors (clinicaltrials.gov) - P2; N=120; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Jun 2017 ➔ Mar 2018

Trial primary completion date • Biosimilar • Hematological Malignancies • Neuroendocrine Tumor

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer (clinicaltrials.gov) - P3; N=500; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Aug 2011 ➔ Jun 2019

Trial primary completion date • Biosimilar • Bladder Cancer • Hematological Malignancies • Prostate Cancer • Reperfusion Injury • Urethral Cancer

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - P2; N=168; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Gastrointestinal Cancer • Hematological Malignancies • Hemophilia • Melanoma • Reperfusion Injury

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - P2; N=88; Completed; Sponsor: National Cancer Institute (NCI); Active, not recruiting ➔ Completed; Trial primary completion date: Dec 2017 ➔ Aug 2017

Trial completion • Trial primary completion date